Aldeyra Therapeutics Report the Results for ADX-629 in P-II Trial for the Treatment of Atopic Dermatitis
Shots:
- The P-II trial evaluates ADX-629 (250mg, BID) in patients with mild to moderate atopic dermatitis for a duration of 3mos. The 1EPs of the study include safety & tolerability & 2EPs include EASI, IGA, POEM, Peak Pruritus Numerical Rating Scale, time to flare, HAM-D & BAI
- The study depicted a significant improvement in EASI with 50% of patients showing improvement in EASI-50, 90% in EASI-75 & 13% in EASI-90. Moreover, 13% of patients achieved complete clearance of affected body surface area, 13% had improvement in IGA, 38% & 25% of patients reported elimination in itching & improvements in HAM-D & BAI were also seen
- ADX-629 is a RASP modulator developed for the treatment of immune-mediated diseases
Ref: Aldeyra | Image: Aldreya
Related News:- Aldeyra Therapeutics Reports First Patient Enrolment in the P-II Trial Evaluating ADX-629 in Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
